CMV INFECTIONS IN AIDS PATIENTS ON ANTI-VIRAL CLINICAL PROTOCOLS

接受抗病毒临床治疗的艾滋病患者的巨细胞病毒感染

• 批准号: 5200715
• 负责人: J F MANISCHEWITZ
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5200715
• 关键词: AIDS therapy; Herpesviridae disease; adenine analog; antiAIDS agent; antiviral agents; clinical trials; combination chemotherapy; cytomegalovirus; cytosine analog; diagnostic respiratory lavage; drug screening /evaluation; flow cytometry; human immunodeficiency virus 1; human subject; human therapy evaluation; immunoglobulins; immunotherapy; interferon alpha; interleukin 2; microorganism disease chemotherapy; opportunistic infections; zidovudine

(1) Goals of Project: - Since CMV is recognized as one of the leading opportunistic infections in AIDS patients, it is important to monitor blood, urine, and tissue specimens from patients enrolled in various clinical trials for the presence of CMV. - Standardization of assays to determine the susceptibility of CMV isolates to various drugs. - Development of a rapid detection system based on Flow cytometry to determine the susceptibility of CMV primary isolates to anti-viral drugs. - Our laboratory participates in the NIAID/ACTG co-pathogen working group committee for the standardization of CMV viral burden assays around the country. (2) Subjects of Clinical Protocols: (a) Combination therapies against HIV-1 : AZT/IL2, IFN-alpha /IL2, and a three arm trial of combination AZT, IFN, and AZT/IFN. (b) A randomized double blind trial to determine the efficacy of CMV-IG as prophylaxis for CMV infections in AIDS patients. Manuscript in preparation. (c) Phase I trial with a Cytosine derivative (HPMPC) for the prevention and/or treatment of CMV infections in AIDS patients. Publication: (1) M. Polis et al. 1955. Anticytomegaloviral activity and safety of Citofovir in patients with human HIV infection and CMV viruria. Antimicrobial Agents and Chemotherapy 39: 882. (d) Phase I trial of an Adenine analog (PMEA) as a potential drug with dual anti- viral effects on HIV-1 and Herpes viruses. (patient population: AIDS with CD4 < 200). Study was terminated. (e) Another goal of this project is to determine if CMV can be isolated from bronchial lavage specimens taken from asymptomatic as well as symptomatic HIV-1 patients. It may provide an early indicator of reactivated CMV in these patients, and lead to early initiation of anti-CMV treatment to prevent systemic fulminating disease. Manuscript in preparation.

(1)项目目标： - 由于巨细胞病毒是公认的主要机会性感染之一， 对于艾滋病患者，监测血液、尿液和组织是很重要的 来自参加各种临床试验的患者的样本， CMV的存在。 - CMV敏感性测定方法的标准化 分离到各种药物。 - 基于流式细胞术的快速检测系统的研制 确定CMV原代分离株对抗病毒药物的敏感性 毒品 - 本实验室参与NIAID/ACTG共病原体工作 巨细胞病毒病毒负荷测定标准化小组委员会 在全国各地。 (2)临床方案受试者： (a)针对HIV-1的联合疗法：AZT/IL 2、IFN-α/IL 2和 AZT、IFN和AZT/IFN组合的三组试验。 (b)确定CMV-IG疗效的随机双盲试验 预防艾滋病患者的巨细胞病毒感染。手稿 准备. (c)使用胞嘧啶衍生物（HPMPC）预防的I期试验 和/或治疗AIDS患者中的CMV感染。 出版物：（1） M. Polis et al. 1955.抗巨细胞病毒活性和安全性 西妥福韦在人类HIV感染和CMV病毒尿症患者中的应用 抗菌药物和化疗39：882。 (d)腺嘌呤类似物（PMEA）作为潜在药物的I期试验， 对HIV-1和疱疹病毒有双重抗病毒作用。（患者 艾滋病患者CD 4 < 200）。 研究终止。 (e)这个项目的另一个目标是确定巨细胞病毒是否可以被隔离 从无症状以及 有症状的HIV-1患者。它可能提供了一个早期指标， 在这些患者中重新激活CMV，并导致早期启动 抗CMV治疗以预防全身暴发性疾病。 手稿 正在筹备中。